Program

This session will focus on the importance of comprehensive genomic profiling, including different methods. Case studies on NTRK positive tumours treated with larotrectinib will be discussed, including the role of treatment holidays. In addition, this session will provide attendees with practical information on larotrectinib dosing, navigating PBS access and item numbers, as well as ordering larotrectinib.

Chairperson: Associate Professor Wayne Nicholls

Targeted therapies in paediatrics – a case study on NTRK fusion
Dr Shampavi Sri Haran, Children’s Health Queensland Hospital and Health Service

Sponsored by Bayer

Plenary 7
Chairpersons: Dr Chris Fraser and Dr Shanti Ramachandran

Curative Treatment Options for Thalassemia and Sickle Cell Disease in 2025
Prof Selim Corbacioglu, University of Regensburg
Involvement made possible by Jazz Pharmaceuticals

Plenary 8
Chairpersons: Jill Shergold and Dr Rachael Lawson

CINV Management: The Easy, The Not-So-Easy, and The Unruly
Prof Lee Dupuis, SickKids

Mapping Proteomic Differences between High-Risk and Non-High-Risk Neuroblastoma
Miss Urwah Nawaz, Children’s Medical Research Institute

Strengthening Paediatric Cancer and Palliative Care Capacity in Papua New Guinea
Dr Gwenda Anga, Port Moresby General Hospital
Involvement made possible by QUT Palliative Care

Inborn errors of immunity in the Haematology clinic.
Dr Peter McNaughton, Queensland Children’s Hospital

Quality of life, distress and support needs of families of children with high-risk sarcoma enrolled in a precision medicine trial
Dr Bhavna Padhye, The Children’s Hospital At Westmead

Approach to Philadelphia-Negative Myeloproliferative Neoplasms in Children
Dr Denitza Mironova, Perth Children’s Hospital

The STAMP Inhibitor asciminib is a Novel Therapy for ABL1-rearranged ALL
Dr Laura Eadie, South Australian Health and Medical Research Institute

Equity in focus: data-driven insights into Aboriginal and Torres Strait Islander childhood cancer
Dr Danica Cossio, Cancer Alliance Queensland

What’s new in Sickle cell disease ?
Dr Anthea Greenway, Royal Children’s Hospital Melbourne

Thematic analysis of the key factors that guide oncologist decisions to use precision-guided treatment in paediatric cancer
Miss Xian Zou, University New South Wales

Current Incidence And Outcome Of Childhood Cancer In Fiji: A Baseline For The Global Initiative For Childhood Cancer
Dr Siobhan Cross, Health NZ

Expanding the Aplastic Anaemia and Other Bone Marrow Failure Registry (AAR) to New Zealand – Exploring epidemiology, availability of diagnostic testing, and genomic profiles
Dr Nathanael Lucas, Monash University and The University of Otago

PREDICT and Validate: Decoding the Genome of Childhood Cancer Predisposition
Miss Safaa Al Haj Hussein, Children’s Hospital at Westmead

Childhood Cancer Survival in Australia: A population-based analysis of prognostic indicators and survival disparities by geography and socio-economic status
Prof Natalie Bradford, Queensland University of Technology

What Should We Research? Defining Priorities for Paediatric Haematopoietic Stem Cell Transplant (HSCT) Through Stakeholder Engagement
Ms Roxanne Dyas, Murdoch Childrens Research Institute

Derivation of a Proteomic Signature for Prediction of Relapse in Paediatric Acute Lymphoblastic Leukaemia
Dr Veronica Yeung, Children’s Medical Research Institute

Quantifying the social and economic burden of childhood cancer on New Zealand families and the impact of location, ethnicity and cancer type
Dr Anna Timmings, Te Whatu Ora – Lakes

Using two example cases, this session will explore some of the key questions and evolving considerations in the management of high-risk neuroblastoma including management of refractory disease at the end of induction and approaches to ongoing care and surveillance following completion of standard upfront therapy. Case examples will be followed by brief presentations on relevant background information and time for open and interactive discussion between speakers and attendees.

Chairperson: Dr Shampavi Sri Haran

Current Dilemmas and Advances in High-Risk Neuroblastoma Management
Dr Daniel Morgenstern, Sick Kids Hospital
Dr Toby Trahair, Sydney Children’s Hospital
Dr Shampavi Sri Haran, Queensland Children’s Hospital

Sponsored by Norgine

SMARCB1 and rhabdoid tumours: germline versus acquired pathogenic variants
Miss Noemi Fuentes Bolano, Sydney Children’s Hospital and Children’s Cancer Institute

Supportive care for patients on novel therapies
Dr Neha Jain, Perth Children’s Hospital

Is Cord Blood Transplant the best stem cell source ins difficult AML; Exploiting Graft versus Leukaemia
Prof Robert Wynn,Manchester University NHS FT

Variations of rotationplasty surgical techniques and implications for physiotherapy in four children at the Queensland Children’s Hospital
Ms Elise Mosey, Children’s Health Queensland

Elevated plasma CXCL9 and CHI3L1 prior to haematopoietic stem cell transplant predict post transplant lung complications in children
Dr Hannah Walker, The Royal Children’s Hospital

New combinations for HR-NB through systematic drug screening and rational targeting of relapse pathways in clinical trial-like PDX studies
Mr Brandon Hearn, Children’s Cancer Institute

Pharmacogenomics in Paediatric Oncology: Australian Patient and Caregiver Perspectives
Ms Claire Moore, Murdoch Children’s Research Institute

Antibiotic-Induced Ablation of Gut Microbiota in Murine Models of Acute Lymphoblastic Leukaemia Results in Variable Patterns of Leukaemic Cell Engraftment
Ms Cate Cheney, South Australian Health and Medical Research Institute

Defining mechanisms of cisplatin resistance in osteosarcoma using a whole genome CRISPR activation screen
Dr Elise Young, Monash Health and Hudson Institute

Y-Site Compatibility of Ketamine with Other Commonly Administered Drugs in Pediatric Oncology
Mr Johnathan Soggee, Perth Children’s Hospital

Addressing caregiver unmet information needs at end-of treatment for acute lymphoblastic leukaemia: The Emerge Program
Dr Cinzia De Luca, Children’s Cancer Centre

Journey mapping of paediatric patients with orthopaedic sarcoma: challenges and support needs identified
Mrs Caitlin Smith, Perth Children’s Hospital

Clinical characterisation and early intervention for the physically vulnerable child with cancer: protocol for a mixed-methods pilot RCT
Dr Sarah Grimshaw, Murdoch Children’s Research Institute

Next generation sequencing (NGS) for detection and monitoring of minimal residual disease in acute lymphoblastic leukaemia
Dr Nicola Mason, The Children’s Hospital at Westmead

Nasopharyngeal Carcinoma in paediatrics and AYA patients: Trial updates
Dr Hetel Dholaria, Perth Children’s Hospital

A Surveillance Study in Multi-Organ Cancer Predisposition Syndromes in Paediatrics (SMOC Junior): Preliminary Results
Dr Noemi Fuentes Bolanos, Sydney Children’s Hospital and Children’s Cancer Institute

Innovative Approach to Physiotherapy Management of Children with Respiratory Complications of Haematopoietic Stem Cell Transplant
Ms Joanne Leavitt, Queensland Children’s Hospital

Identification of molecular prognostic and therapy resistance signatures in childhood and AYA osteosarcomas
Dr Nataliya Zhukova, Hudson Institute of Medical Research

Body Composition Changes in Early Survivors of Childhood Brain Tumours: Data from the CARaB C Study
Dr Erin Sharwood, Children’s Health Queensland

Acquired copy number variants are highly correlated with Ph+ALL subgroups identified by transcriptomic analysis
Dr Jacqueline Rehn, South Australian Health and Medical Research Institute

Plenary 9
Chairpersons: Dr Pasquale Barbaro and Dr Sally Campbell

Emerging therapies in inherited bleeding disorders
Dr Jane Mason, Royal Brisbane and Women’s Hospital

ANZCHOG 2025 ASM Best Abstracts
Chairperson: Dr Rick Walker, Jessica Nicholson and Kirt Myers

Queensland Youth Cancer Service: Prioritising Adolescent and Young Adult futures through connection and wrap around care
Mrs Tracy Till, Queensland Children’s Hospital

Potential for Pharmacogenomics to Improve Medication Safety and Efficacy in Australian Paediatric Oncology Patients
Ms Claire Moore, Murdoch Children’s Research Institute

Using Methylation Array Profiling for Juvenile Myelomonocytic Leukaemia Classification
Dr Christine White, Victorian Clinical Genetics Services

Exploring Symptom Burden and Symptom Clusters in Childhood and Adolescent Cancer Survivors: A Multi-perspective Cross-sectional Study
Dr Sarah Ellis, University New South Wales

Towards a National System for Minimally Invasive Monitoring of any Childhood Cancer: Lessons Learnt and Opportunities for Impact
Mr Rob Salomon, Children’s Cancer Institute

Dress code: Cocktail
Information: An elegant evening of celebration featuring a three course dinner, drinks, and the abstract awards. Set in one of the city’s most iconic venues, this special night offers the perfect opportunity to connect with colleagues and honour excellence in our field.